{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:47:47Z","timestamp":1790347667654,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["189043"],"award-info":[{"award-number":["189043"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008038","name":"Neuromuscular Research Association Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Myasthenia gravis is an autoimmune disorder defined by muscle weakness and fatigability associated with antibodies against proteins of the neuromuscular junction (NMJ). The most common autoantibody target is the acetylcholine receptor (AChR). Three mechanisms have been postulated by which autoantibodies might interfere with neurotransmission: direct antagonism of the receptor, complement-mediated destruction of the postsynaptic membrane, and enhanced internalization of the receptor. It is very likely that more than one of these mechanisms act in parallel. Dissecting the mechanisms of autoantibody-mediated pathology requires patient-derived, monoclonal antibodies. Using membrane antigen capture activated cell sorting (MACACS), we isolated AChR-specific B cells from patients with myasthenia gravis, and produced six recombinant antibodies. All AChR-specific antibodies were hypermutated, including isotypes IgG\n                    <jats:sub>1<\/jats:sub>\n                    , IgG\n                    <jats:sub>3<\/jats:sub>\n                    , and IgG\n                    <jats:sub>4<\/jats:sub>\n                    , and recognized different subunits of the AChR. Despite clear binding, none of the individual antibodies showed significant antagonism of the AChR measured in an in vitro neuromuscular synapse model, or AChR-dependent complement activation, and they did not induce myasthenic signs in vivo. However, combinations of antibodies induced strong complement activation in vitro, and severe weakness in a passive transfer myasthenia gravis rat model, associated with NMJ destruction and complement activation in muscle. The strongest complement activation was mediated by combinations of antibodies targeting disparate subunits of the AChR, and such combinations also induced the formation of large clusters of AChR on the surface of live cells in vitro. We propose that synergy between antibodies of different epitope specificities is a fundamental feature of this disease, and possibly a general feature of complement-mediated autoimmune diseases. The importance of synergistic interaction between antibodies targeting different subunits of the receptor can explain the well-known discrepancy between serum anti-AChR titers and clinical severity, and has implications for therapeutic strategies currently under investigation.\n                  <\/jats:p>","DOI":"10.1007\/s00401-022-02493-6","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T10:03:07Z","timestamp":1662631387000},"page":"1005-1025","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities"],"prefix":"10.1007","volume":"144","author":[{"given":"Natalie","family":"Rose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Holdermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Callegari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyein","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Fruh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1711-7275","authenticated-orcid":false,"given":"Nicholas S. R.","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Derfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"2493_CR1","doi-asserted-by":"publisher","DOI":"10.15252\/EMBR.202153956","author":"I Callegari","year":"2022","unstructured":"Callegari I, Schneider M, Berloffa G, M\u00fchlethaler T, Holdermann S, Galli E et al (2022) Potent neutralization by monoclonal human IgM against SARS-CoV-2 is impaired by class switch. EMBO Rep. https:\/\/doi.org\/10.15252\/EMBR.202153956","journal-title":"EMBO Rep"},{"issue":"499","key":"2493_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nature12354","volume":"4997458","author":"TW Chen","year":"2013","unstructured":"Chen TW, Wardill TJ, Sun Y, Pulver SR, Renninger SL, Baohan A et al (2013) Ultrasensitive fluorescent proteins for imaging neuronal activity. Nat 4997458(499):295\u2013300. https:\/\/doi.org\/10.1038\/nature12354","journal-title":"Nat"},{"key":"2493_CR3","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","volume":"16","author":"MC Dalakas","year":"2020","unstructured":"Dalakas MC, Alexopoulos H, Spaeth PJ (2020) Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol 16:601\u2013617. https:\/\/doi.org\/10.1038\/s41582-020-0400-0","journal-title":"Nat Rev Neurol"},{"key":"2493_CR4","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.1248943","volume":"343","author":"CA Diebolder","year":"2014","unstructured":"Diebolder CA, Beurskens FJ, De Jong RN, Koning RI, Strumane K, Lindorfer MA et al (2014) Complement is activated by IgG hexamers assembled at the cell surface. Science (80-) 343:1260\u20131263. https:\/\/doi.org\/10.1126\/science.1248943","journal-title":"Science (80-)"},{"key":"2493_CR5","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1056\/nejm198209233071301","volume":"307","author":"DB Drachman","year":"1982","unstructured":"Drachman DB, Adams RN, Josifek LF, Self SG (1982) Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 307:769\u2013775. https:\/\/doi.org\/10.1056\/nejm198209233071301","journal-title":"N Engl J Med"},{"key":"2493_CR6","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/nejm197805182982004","volume":"298","author":"DB Drachman","year":"1978","unstructured":"Drachman DB, Angus CW, Adams RN, Michelson JD, Hoffman GJ (1978) Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med 298:1116\u20131122. https:\/\/doi.org\/10.1056\/nejm197805182982004","journal-title":"N Engl J Med"},{"key":"2493_CR7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","volume":"505","author":"AG Engel","year":"1987","unstructured":"Engel AG, Arahata K (1987) The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci 505:326\u2013332. https:\/\/doi.org\/10.1111\/j.1749-6632.1987.tb51301.x","journal-title":"Ann N Y Acad Sci"},{"key":"2493_CR8","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1096\/fj.13-239012","volume":"28","author":"A Faleri","year":"2014","unstructured":"Faleri A, Santini L, Brier S, Pansegrau W, Lo SP, Scarselli M et al (2014) Two cross-reactive monoclonal antibodies recognize overlapping epitopes on Neisseria meningitidis factor H binding protein but have different functional properties. FASEB J 28:1644\u20131653. https:\/\/doi.org\/10.1096\/fj.13-239012","journal-title":"FASEB J"},{"key":"2493_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM (2019) Myasthenia gravis. Nat Rev Dis Prim. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Prim"},{"key":"2493_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3109\/08916938809010682","volume":"1","author":"F Heidenreich","year":"1988","unstructured":"Heidenreich F, Vincent A, Roberts A, Newsom-Davis J (1988) Epitopes on human acetylcholine receptor defined by monoclonal antibodies and myasthenia gravis sera. Autoimmunity 1:285\u2013297. https:\/\/doi.org\/10.3109\/08916938809010682","journal-title":"Autoimmunity"},{"key":"2493_CR11","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1212\/WNL.38.11.1784","volume":"38","author":"F Heidenreich","year":"1988","unstructured":"Heidenreich F, Vincent A, Willcox N, Newsom-Davis J (1988) Anti-acetylcholine receptor antibody specificities in serum and in thymic cell culture supernatants from myasthenia gravis patients. Neurology 38:1784\u20131788. https:\/\/doi.org\/10.1212\/WNL.38.11.1784","journal-title":"Neurology"},{"issue":"29","key":"2493_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nbt.1927","volume":"298","author":"D Hockemeyer","year":"2011","unstructured":"Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP et al (2011) Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 298(29):731\u2013734. https:\/\/doi.org\/10.1038\/nbt.1927","journal-title":"Nat Biotechnol"},{"key":"2493_CR13","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Robeson K et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"key":"2493_CR14","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/J.1749-6632.1987.TB51321.X","volume":"505","author":"FM Howard","year":"1987","unstructured":"Howard FM, Lennon VA, Finley J, Matsumoto J, Elveback LR (1987) Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci 505:526\u2013538. https:\/\/doi.org\/10.1111\/J.1749-6632.1987.TB51321.X","journal-title":"Ann N Y Acad Sci"},{"key":"2493_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000547","author":"MG Huijbers","year":"2019","unstructured":"Huijbers MG, Vergoossen DL, Filli\u00e9-Grijpma YE, Van Es IE, Koning MT, Slot LM et al (2019) MuSK myasthenia gravis monoclonal antibodies: valency dictates pathogenicity. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000547","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2493_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/bjh.12503","volume":"163","author":"JL Klitgaard","year":"2013","unstructured":"Klitgaard JL, Koefoed K, Geisler C, Gadeberg OV, Frank DA, Petersen J et al (2013) Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells. Br J Haematol 163:182\u2013193. https:\/\/doi.org\/10.1111\/bjh.12503","journal-title":"Br J Haematol"},{"key":"2493_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0108327","author":"G Kordas","year":"2014","unstructured":"Kordas G, Lagoumintzis G, Sideris S, Poulas K, Tzartos SJ (2014) Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients. PLoS ONE. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0108327","journal-title":"PLoS ONE"},{"key":"2493_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.expneurol.2015.02.025","volume":"270","author":"LL Kusner","year":"2015","unstructured":"Kusner LL, Losen M, Vincent A, Lindstrom J, Tzartos S, Lazaridis K et al (2015) Guidelines for pre-clinical assessment of the acetylcholine receptor-specific passive transfer myasthenia gravis model-recommendations for methods and experimental designs. Exp Neurol 270:3\u201310. https:\/\/doi.org\/10.1016\/j.expneurol.2015.02.025","journal-title":"Exp Neurol"},{"key":"2493_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jneuroim.2016.12.011","volume":"303","author":"K Lazaridis","year":"2017","unstructured":"Lazaridis K, Baltatzidi V, Trakas N, Koutroumpi E, Karandreas N, Tzartos SJ (2017) Characterization of a reproducible rat EAMG model induced with various human acetylcholine receptor domains. J Neuroimmunol 303:13\u201321. https:\/\/doi.org\/10.1016\/j.jneuroim.2016.12.011","journal-title":"J Neuroimmunol"},{"key":"2493_CR20","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/BRAIN\/AWN092","volume":"131","author":"MI Leite","year":"2008","unstructured":"Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP et al (2008) IgG1 antibodies to acetylcholine receptors in \u201cseronegative\u201d myasthenia gravis. Brain 131:1940\u20131952. https:\/\/doi.org\/10.1093\/BRAIN\/AWN092","journal-title":"Brain"},{"key":"2493_CR21","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/wnl.39.8.1069","volume":"39","author":"VA Lennon","year":"1989","unstructured":"Lennon VA, Griesmann GE (1989) Evidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravis. Neurology 39:1069\u20131076. https:\/\/doi.org\/10.1212\/wnl.39.8.1069","journal-title":"Neurology"},{"key":"2493_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-017-01019-5","author":"M Losen","year":"2017","unstructured":"Losen M, Labrijn AF, Van Kranen-Mastenbroek VH, Janmaat ML, Haanstra KG, Beurskens FJ et al (2017) Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys. Sci Rep. https:\/\/doi.org\/10.1038\/S41598-017-01019-5","journal-title":"Sci Rep"},{"key":"2493_CR23","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1002\/eji.1830220939","volume":"22","author":"H Loutrari","year":"1992","unstructured":"Loutrari H, Kokla A, Tzartos SJ (1992) Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur J Immunol 22:2449\u20132452. https:\/\/doi.org\/10.1002\/eji.1830220939","journal-title":"Eur J Immunol"},{"key":"2493_CR24","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/J.BCP.2015.07.011","volume":"97","author":"J Luo","year":"2015","unstructured":"Luo J, Lindstrom J (2015) AChR-specific immunosuppressive therapy of myasthenia gravis. Biochem Pharmacol 97:609\u2013619. https:\/\/doi.org\/10.1016\/J.BCP.2015.07.011","journal-title":"Biochem Pharmacol"},{"key":"2493_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185976","author":"T Makino","year":"2017","unstructured":"Makino T, Nakamura R, Terakawa M, Muneoka S, Nagahira K, Nagane Y et al (2017) Analysis of peripheral B cells and autoantibodies against the anti-nicotinic acetylcholine receptor derived from patients with myasthenia gravis using single-cell manipulation tools. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0185976","journal-title":"PLoS ONE"},{"key":"2493_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"S Muppidi","year":"2019","unstructured":"Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Robeson K et al (2019) Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60:14\u201324. https:\/\/doi.org\/10.1002\/mus.26447","journal-title":"Muscle Nerve"},{"key":"2493_CR27","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1126\/science.1144603","volume":"317","author":"M Van Der NeutKolfschoten","year":"2007","unstructured":"Van Der NeutKolfschoten M, Schuurman J, Losen M, Bleeker WK, Mart\u00ednez-Mart\u00ednez P, Vermeulen E et al (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317:1554\u20131557. https:\/\/doi.org\/10.1126\/science.1144603","journal-title":"Science"},{"key":"2493_CR28","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1212\/wnl.28.3.266","volume":"28","author":"J Newsom-Davis","year":"1978","unstructured":"Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG (1978) Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange. Neurology 28:266\u2013272. https:\/\/doi.org\/10.1212\/wnl.28.3.266","journal-title":"Neurology"},{"key":"2493_CR29","doi-asserted-by":"publisher","first-page":"13829","DOI":"10.1074\/jbc.M112.344325","volume":"287","author":"PW Phuan","year":"2012","unstructured":"Phuan PW, Ratelade J, Rossi A, Tradtrantip L, Verkman AS (2012) Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. J Biol Chem 287:13829\u201313839. https:\/\/doi.org\/10.1074\/jbc.M112.344325","journal-title":"J Biol Chem"},{"key":"2493_CR30","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1152\/physrev.1984.64.4.1162","volume":"64","author":"JL Popot","year":"1984","unstructured":"Popot JL, Changeux JP (1984) Nicotinic receptor of acetylcholine: structure of an oligomeric integral membrane protein. Physiol Rev 64:1162\u20131239. https:\/\/doi.org\/10.1152\/physrev.1984.64.4.1162","journal-title":"Physiol Rev"},{"key":"2493_CR31","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1172\/jci105926","volume":"47","author":"WF Rosse","year":"1969","unstructured":"Rosse WF (1969) Fixation of the first component of complement (C\u2019la) by human antibodies. J Clin Investig 47:2430\u20132445. https:\/\/doi.org\/10.1172\/jci105926","journal-title":"J Clin Investig"},{"issue":"8","key":"2493_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-20064-2","volume":"81","author":"OM Russell","year":"2018","unstructured":"Russell OM, Fruh I, Rai PK, Marcellin D, Doll T, Reeve A et al (2018) Preferential amplification of a human mitochondrial DNA deletion in vitro and in vivo. Sci Rep 81(8):1\u201310. https:\/\/doi.org\/10.1038\/s41598-018-20064-2","journal-title":"Sci Rep"},{"key":"2493_CR33","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41565-018-0336-3","volume":"14","author":"A Shaw","year":"2019","unstructured":"Shaw A, Hoffecker IT, Smyrlaki I, Rosa J, Grevys A, Bratlie D et al (2019) Binding to nanopatterned antigens is dominated by the spatial tolerance of antibodies. Nat Nanotechnol 14:184\u2013190. https:\/\/doi.org\/10.1038\/s41565-018-0336-3","journal-title":"Nat Nanotechnol"},{"issue":"10","key":"2493_CR34","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nchembio.1550","volume":"108","author":"Y Smurnyy","year":"2014","unstructured":"Smurnyy Y, Cai M, Wu H, McWhinnie E, Tallarico JA, Yang Y et al (2014) DNA sequencing and CRISPR-Cas9 gene editing for target validation in mammalian cells. Nat Chem Biol 108(10):623\u2013625. https:\/\/doi.org\/10.1038\/nchembio.1550","journal-title":"Nat Chem Biol"},{"key":"2493_CR35","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1172\/JCI122942","volume":"129","author":"J Soltys","year":"2019","unstructured":"Soltys J, Liu Y, Ritchie A, Wemlinger S, Schaller K, Schumann H et al (2019) Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica. J Clin Investig 129:2000\u20132013. https:\/\/doi.org\/10.1172\/JCI122942","journal-title":"J Clin Investig"},{"key":"2493_CR36","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mus.23247","volume":"45","author":"C Song","year":"2012","unstructured":"Song C, Xu Z, Miao J, Xu J, Wu X, Zhang F et al (2012) Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: a possible option for treatment of myasthenia gravis. Muscle Nerve 45:668\u2013675. https:\/\/doi.org\/10.1002\/mus.23247","journal-title":"Muscle Nerve"},{"key":"2493_CR37","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1021\/acs.nanolett.9b02220","volume":"19","author":"J Strasser","year":"2019","unstructured":"Strasser J, De Jong RN, Beurskens FJ, Wang G, Heck AJR, Schuurman J et al (2019) Unraveling the macromolecular pathways of IgG oligomerization and complement activation on antigenic surfaces. Nano Lett 19:4787\u20134796. https:\/\/doi.org\/10.1021\/acs.nanolett.9b02220","journal-title":"Nano Lett"},{"key":"2493_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/FNMOL.2020.00086","author":"M Takamori","year":"2020","unstructured":"Takamori M (2020) Myasthenia gravis: from the viewpoint of pathogenicity focusing on acetylcholine receptor clustering, trans-synaptic homeostasis and synaptic stability. Front Mol Neurosci. https:\/\/doi.org\/10.3389\/FNMOL.2020.00086","journal-title":"Front Mol Neurosci"},{"key":"2493_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127167","author":"K Takata","year":"2019","unstructured":"Takata K, Stathopoulos P, Cao M, Man\u00e9-Damas M, Fichtner ML, Benotti ES et al (2019) Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.127167","journal-title":"JCI Insight"},{"key":"2493_CR40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJM197701202960301","volume":"296","author":"KV Toyka","year":"1977","unstructured":"Toyka KV, Drachman DB, Griffin DE, Pestronk A, Winkelstein JA, Fishbeck KH et al (1977) Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med 296:125\u2013131","journal-title":"N Engl J Med"},{"key":"2493_CR41","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1212\/wnl.39.10.1359","volume":"39","author":"M Tsujihata","year":"1989","unstructured":"Tsujihata M, Yoshimura T, Satoh A, Kinoshita I, Matsuo H, Mori M et al (1989) Diagnostic significance of igg, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis. Neurology 39:1359\u20131363. https:\/\/doi.org\/10.1212\/wnl.39.10.1359","journal-title":"Neurology"},{"key":"2493_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1600-065X.1998.tb01190.x","volume":"163","author":"SJ Tzartos","year":"1998","unstructured":"Tzartos SJ, Barkas T, Cung MT, Mamalaki A, Marraud M, Orlewski P et al (1998) Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev 163:89\u2013120. https:\/\/doi.org\/10.1111\/j.1600-065X.1998.tb01190.x","journal-title":"Immunol Rev"},{"key":"2493_CR43","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1073\/pnas.79.1.188","volume":"79","author":"SJ Tzartos","year":"1982","unstructured":"Tzartos SJ, Seybold ME, Lindstrom JM (1982) Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sci USA 79:188\u2013192. https:\/\/doi.org\/10.1073\/pnas.79.1.188","journal-title":"Proc Natl Acad Sci USA"},{"key":"2493_CR44","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","volume":"357","author":"A Vincent","year":"2001","unstructured":"Vincent A, Palace J, Hilton-Jones D (2001) Myasthenia gravis. Lancet 357:2122\u20132128. https:\/\/doi.org\/10.1016\/S0140-6736(00)05186-2","journal-title":"Lancet"},{"key":"2493_CR45","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDOA2100066","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R et al (2022) Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. https:\/\/doi.org\/10.1056\/EVIDOA2100066","journal-title":"NEJM Evid"},{"key":"2493_CR46","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1212\/WNL.36.5.612","volume":"36","author":"PJ Whiting","year":"1986","unstructured":"Whiting PJ, Vincent A, Newsom-Davis J (1986) Myasthenia gravis: monoclonal antihuman acetylcholine receptor antibodies used to analyze antibody specificities and responses to treatment. Neurology 36:612\u2013617. https:\/\/doi.org\/10.1212\/WNL.36.5.612","journal-title":"Neurology"},{"key":"2493_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00829","author":"M Zimmermann","year":"2019","unstructured":"Zimmermann M, Rose N, Lindner JM, Kim H, Gon\u00e7alves AR, Callegari I et al (2019) Antigen extraction and B cell activation enable identification of rare membrane antigen specific human B cells. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.00829","journal-title":"Front Immunol"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-022-02493-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-022-02493-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-022-02493-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T10:06:12Z","timestamp":1665223572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-022-02493-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2493"],"URL":"https:\/\/doi.org\/10.1007\/s00401-022-02493-6","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"assertion":[{"value":"24 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}